ARTICLE | Company News
Panel split on Novartis' Diovan
October 11, 2001 7:00 AM UTC
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 4-4 on whether to recommend approval of NVS's sNDA for Diovan valsartan angiotensin II receptor antagonist to treat heart failure. The...